Hamburg-based biotech company Topas Therapeutics has closed a €22m series-B round co-led by new investors Vesalius BioCapital III and BioMedPartners.
Hamburg-based biotech company Topas Therapeutics has closed a €22m series-B round co-led by new investors Vesalius BioCapital III and BioMedPartners.